Form 8-K - Current report:
SEC Accession No. 0001104659-22-051588
Filing Date
2022-04-28
Accepted
2022-04-28 06:35:40
Documents
16
Period of Report
2022-04-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2213615d1_8k.htm   iXBRL 8-K 34631
2 EXHIBIT 99.1 tm2213615d1_ex99-1.htm EX-99.1 347900
3 EXHIBIT 99.2 tm2213615d1_ex99-2.htm EX-99.2 524093
8 GRAPHIC tm2213615d1_ex99-1img001.jpg GRAPHIC 4280
  Complete submission text file 0001104659-22-051588.txt   1201035

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrk-20220428.xsd EX-101.SCH 4152
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20220428_def.xml EX-101.DEF 28239
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20220428_lab.xml EX-101.LAB 38353
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20220428_pre.xml EX-101.PRE 26849
10 EXTRACTED XBRL INSTANCE DOCUMENT tm2213615d1_8k_htm.xml XML 7855
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 22862065
SIC: 2834 Pharmaceutical Preparations